Notable releases from emerging-market stocks: RIBOMIC, circlace, REALGATE and others (FISCO)

Among notable releases from emerging markets, consent to participate in Ribomic's Phase III trial exceeded the target, while Circleace announced a tender offer. Developments at REALGATE and other companies were also reported.

Read in fullFrom the source, not the headline

sources corroborateOutlets reporting the same event

companies linkedAcross 0 themes, second pass

The story

Ribomic reportedly exceeded its target enrollment for consent to participate in the Phase III clinical trial of ume daptanib pegol, a treatment for achondroplasia.

Circleace conducted a tender offer by HHH1 Godo Kaisha, with the offer price set at ¥2,020 per share.

Notable releases from emerging-market companies, including REALGATE, were also highlighted, and further updates are awaited.

At a glance

EventTrial participation consent in the Phase III study of umedaptanib pegol exceeds the target

Tender offer priceTender offer conducted at ¥2,020 per share

Informationumsdaptanib pegol is a treatment for achondroplasia

Reference information. Every claim resolves to something the story actually named.

Where this came from

We read each source in full and checked they agree on the core claim.

1/ 1 agree

All of them report the same thing.

finance.yahoo.co.jpNews

AgreesOpen

Read the original articleGo to the source page

Reference information generated from public sources. It does not solicit or advise on investments. Prices are 15-minute delayed.